This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
peripheral membrane protein Also extrinsic membrane protein. Any of a class of membrane proteins which attach only temporarily to the cell membrane, either by penetrating the lipid bilayer or by attaching to other proteins which are permanently embedded within the membrane. The ability to reversibly interact with membranes makes peripheral membrane proteins important in many different roles, commonly as regulatory subunits of channel proteins and cell surface receptors. Their domains often undergo rearrangement, dissociation, or conformational changes when they interact with the membrane, resulting in the activation of their biological activity. In protein purification, peripheral membrane proteins are typically more water-soluble and much easier to isolate from the membrane than integral membrane proteins.
Drugs active in microgram range, most notably LSD, are commonly distributed illicitly on blotting paper. A liquid solution of the drug is applied to the blotting paper, which commonly is perforated into individual doses and artfully decorated with what is known as blotter art. Vanity blotter is blotter art that has not been exposed to LSD and is usually sold as a collectible, although inevitably much of this art ends up in illegal distribution. The artwork is printed onto blotter paper and then sometimes perforated into tiny squares or "tabs" which can be torn or cut apart. Most blotter art designs have grid lines as part of the design to either aid in perforation or to be left as a cutting grid. Blotter as a drug delivery method allows for easy dosing of potent substances, and easy sublingual administration of drugs which has made it increasingly popular as a preparation for other potent drugs, including 25I-NBOMe and alprazolam. Plain white LSD blotter without artwork is commonly referred to as “WoW” (White on White) and is usually not perforated but rather gridded with a pen and sometimes laid on common watercolour paper.
=== Bond specificity === Bond specificity, unlike group specificity, recognizes particular chemical bond types. This differs from group specificity, as it is not reliant on the presence of particular functional groups in order to catalyze a particular reaction, but rather a certain bond type (for example, a peptide bond).
Sources: en.wikipedia.org
== Decorations == Meritorious Unit Commendation (Army), Streamer embroidered PACIFIC AREA 1972–1973 Meritorious Unit Commendation (Army), Streamer embroidered ASIA 2002 Meritorious Unit Commendation (Army), Streamer embroidered SOUTHWEST ASIA 2014–2015 Army Superior Unit Award, Streamer embroidered 2013 Philippine Presidential Unit Citation, Streamer embroidered JULY-AUGUST 1972 1st Special Forces Battalion elements entitled to: Company A, 1st Special Forces Battalion entitled to: Valorous Unit Award, Streamer embroidered EASTERN AFGHANISTAN FEB-SEP 2012 Company C, 1st Special Forces Battalion entitled to: Valorous Unit Award, Streamer embroidered CENTRAL AND SOUTHERN IRAQ 2007 Valorous Unit Award, Streamer embroidered CENTRAL IRAQ 2008–2009 2nd Special Forces Battalion entitled to:
The linear ion trap (LIT) is a type of ion trap mass spectrometer. In a LIT, ions are confined radially by a two-dimensional radio frequency (RF) field, and axially by stopping potentials applied to end electrodes. LITs have high injection efficiencies and high ion storage capacities.
Le continued developing patches for the game until the release of Counter-Strike 1.0, after which he stepped away from the main title and began work on a prototype for Counter-Strike 2. However, after nearly three years of development, the project was shelved when it was only about 25% complete. With Counter-Strike 2 discontinued, Minh Le turned his attention to developing Day of Defeat: Source. Following its release, he left Valve in 2006 to pursue an independent project. After spending two years working with a small team on the project, he moved to South Korea in 2008 to work with the company named FIX Korea, which provided funding for its continued development. Le's new game was later revealed to be Tactical Intervention, a game similar in style to Counter-Strike created with a modified version of Valve's Source engine. In October 2013, Minh Le joined Facepunch Studios, where he worked on Rust. He remained at the studio until February 2018, when he departed to join Pearl Abyss the following month. There, he worked on MMOFPS game called PLAN 8. Le left Pearl Abyss in 2023. Minh Le later continued working in small-team and independent game development. His later projects included Alpha Response, a tactical PvE shooter released in early access. In 2026, Le said he had considered returning to work on Counter-Strike 2, particularly on weapon animations and maps, while also stating that he believed Counter-Strike was "in a really good space".
=== Before blood donation === G-CSF is also used to increase the number of hematopoietic stem cells in the blood of the donor before collection by leukapheresis for use in hematopoietic stem cell transplantation. For this purpose, G-CSF appears to be safe in pregnancy during implantation as well as during the second and third trimesters. Breastfeeding should be withheld for three days after CSF administration to allow for clearance of it from the milk. People who have been administered colony-stimulating factors do not have a higher risk of leukemia than people who have not.
Sources: en.wikipedia.org
=== Non-specific detection: real-time PCR with double-stranded DNA-binding dyes as reporters === A DNA-binding dye binds to all double-stranded (ds) DNA in PCR, increasing the fluorescence quantum yield of the dye. An increase in DNA product during PCR therefore leads to an increase in fluorescence intensity measured at each cycle. However, dsDNA dyes such as SYBR Green will bind to all dsDNA PCR products, including nonspecific PCR products (such as primer dimer). This can potentially interfere with, or prevent, accurate monitoring of the intended target sequence. In real-time PCR with dsDNA dyes the reaction is prepared as usual, with the addition of fluorescent dsDNA dye. Then the reaction is run in a real-time PCR instrument, and after each cycle, the intensity of fluorescence is measured with a detector; the dye only fluoresces when bound to the dsDNA (i.e., the PCR product). This method has the advantage of only needing a pair of primers to carry out the amplification, which keeps costs down; multiple target sequences can be monitored in a tube by using different types of dyes.
Anne Jamieson Hosie, Executive Officer, the Benefits Agency, Department of Social Security. Ralph John Howe, Gardener, Kettering General Hospital, Northamptonshire. For services to Health Care. Arthur William Howell, leading Firefighter, London Fire and Civil Defence Authority. For services to the Fire Service. Edna Emily Howes. For services to the Royal British Legion in Northamptonshire. Denis Arthur Huggons. For services to the London Gardens Society. Margaret Florence Hughes, Postwoman, Royal Mail. For services to the Post Office and to the community in Wollaston, Northamptonshire. Mildred Emily Hughes, Chief Clerk, Llangefni County Court, Lord Chancellor's Department. David Bain Hume, Director, Philomusica. For services to Music in Edinburgh. Dorothy Hunt. For services to the Sea Cadet Corps in Nottingham. Sarah Ruth Hunt. For services to Disabled Children in Northampton. Marion Hunter. For services to the Fire Service. John Malcolm Huntington. For services to Sports Journalism in Yorkshire. Margaret Isobel Hutcheon, Headteacher, Mosstowie Primary School, Morayshire. For services to Education. Helen Rosalind Hutchinson, Tourist Guide. For services to Tourism. Derek Cecil George Hynds, Senior Professional and Technology Officer, Ministry of Defence. Simon Louis Jackson. For services to Judo for Disabled People. Sydney Frederic Jacobs. For services to the community in Liverpool. Arjan Singh Jagdev. For services to the ethnic community in Merton, London. Mary James. For services to Farming and to Consumer Affairs. John Malcolm Jefkins. For political service.
== Legacy == According to The Tuscaloosa News, by the "Great Depression, the ruins of the burned statehouse were dispersed or massed into a low mound with grass on top." In 1988, "a design committee, which included architectural historian Robert Mellown...began extensive historical and archaeological research...and drew up plans to create a ruin." A historical marker in the park commemorates the school's history. The University of Alabama has a collection of papers related to the school. A poem about the old capitol was published. The western end of the 4.5-mile Riverwalk begins at Capitol Park. Located at the South West Corner in the McGuire Strickland House since 1993 is The Capitol School. It is a private school serving students from 6 weeks through High school.
=== Ring-fused pyridines === Benzopyridine, quinoline, is a component of coal tars. It and its derivatives find many uses. Dibenzopyridines are also well known, the symmetrical version being acridine.
== Concerns == Concerns over AI agents include potential issues of liability, an increased risk of cybercrime, ethical challenges, and problems related to AI safety and AI alignment. Other issues involve data privacy, weakened human oversight, a lack of guaranteed repeatability, reward hacking, algorithmic bias, compounding software errors, lack of explainability of agents' decisions, security vulnerabilities, stifling competition, problems with underemployment, job displacement, cognitive offloading, and the potential for user manipulation, misinformation or malinformation. They may also complicate legal and risk-assessment frameworks, foster hallucinations, hinder countermeasures against rogue agents, and suffer from the lack of standardized evaluation methods. Enterprise deployment of AI agents has raised contracting concerns related to liability allocation, data ownership rights, and legal accountability. They have also been criticized for being expensive, having a negative impact on internet traffic, and potentially damaging to the environment due to high energy usage. According to Nvidia CEO Jensen Huang, AI agents would require 100 times more computing power than LLMs. There is also the risk of increased political corruption, as AI agents may not question instructions in the same way that humans would. Journalists have described AI agents as part of a push by Big Tech companies to "automate everything". Several of those companies' CEOs stated in early 2025 that they expect AI agents to eventually "join the workforce".
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.